<DOC>
	<DOCNO>NCT01244048</DOCNO>
	<brief_summary>The effective dosage n3-LC-PUFA intervention ( n3 LC-PUFA-enriched yoghurt ) modulation cardiovascular risk factor inflammatory biomarkers determine .</brief_summary>
	<brief_title>Intervention With n3 LC-PUFA-supplemented Yogurt</brief_title>
	<detailed_description>Fifty three mildly hypertriacylglycerolemic subject ( TAG ≥ 150 mg/dL ( 1.7 mmol/L ) ) participate placebo-controlled , double-blind , parallel design study . The subject consume placebo yoghurt ( 1 ) , n3 LC-PUFA-enriched yoghurt ( 0.8 g n3 LC-PUFA/d ( 2 ) , 3 g n3 LC-PUFA/d ( 3 ) ) 10 week . Blood sample take begin end period . Parameters : - Blood lipid ( total cholesterol , HDL , LDL , triacylglycerols ) - Fatty acid distribution plasma lipid ( PL ) erythrocyte membrane ( EM ) - Concentrations eicosanoids ( PGs , HETEs ) - Production ex vivo stimulate cytokine T cell - SNPs CD36 genotype</detailed_description>
	<criteria>hypertriacylglycerolemic subject ( TAG : ≥ 150 mg/dl ( 1.7 mmol/l ) ) patient receive blooddiluting lipidlowering medication glucocorticoid patient suffer gastrointestinal metabolic disease ( e.g. , diabetes mellitus , hyper hypothyroidism ) hypercholesteremic patient familial previous impact patient take dietary supplement ( e.g. , fish oil capsule , vitamin E ) either known allergy foodstuff indigestibility exclusion criterion : smoking , high sportive activity daily alcohol intake</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>n3 LC-PUFA , yoghurt , inflammatory marker</keyword>
</DOC>